Synonym
Dazopride, Dazopridum, Dazoprida
IUPAC/Chemical Name
Benzamide, 4-amino-5-chloro-N-(1,2-diethyl-4-pyrazolidinyl)-2-methoxy-
InChi Key
YFXIKEZOBJFVAQ-UHFFFAOYSA-N
InChi Code
InChI=1S/C15H23ClN4O2/c1-4-19-8-10(9-20(19)5-2)18-15(21)11-6-12(16)13(17)7-14(11)22-3/h6-7,10H,4-5,8-9,17H2,1-3H3,(H,18,21)
SMILES Code
O=C(NC1CN(CC)N(CC)C1)C2=CC(Cl)=C(N)C=C2OC
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
to be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
|
Solvent |
mg/mL |
mM |
| Solubility |
| To be determined |
0.0 |
100.00 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
326.83
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Costall B, Domeney AM, Gunning SJ, Kelly ME, Naylor RJ, Nohria V, Owera-Atepo JB, Simpson KM, Tan CC, Tattersall D. The action of dazopride to enhance gastric emptying and block emesis. Neuropharmacology. 1987 Jul;26(7A):669-77. doi: 10.1016/0028-3908(87)90227-9. PMID: 3114664.
2: Alphin RS, Proakis AG, Leonard CA, Smith WL, Dannenburg WN, Kinnier WJ, Johnson DN, Sancilio LF, Ward JW. Antagonism of cisplatin-induced emesis by metoclopramide and dazopride through enhancement of gastric motility. Dig Dis Sci. 1986 May;31(5):524-9. doi: 10.1007/BF01320319. PMID: 3698769.
3: Grant SC, Kris MG, Gralla RJ, Clark RA, Tyson LB. Dose-ranging evaluation of the substituted benzamide dazopride when used as an antiemetic in patients receiving anticancer chemotherapy. Cancer Chemother Pharmacol. 1993;31(6):442-4. doi: 10.1007/BF00685032. PMID: 8453682.
4: Villalón CM, den Boer MO, Heiligers JP, Saxena PR. Further characterization, by use of tryptamine and benzamide derivatives, of the putative 5-HT4 receptor mediating tachycardia in the pig. Br J Pharmacol. 1991 Jan;102(1):107-12. doi: 10.1111/j.1476-5381.1991.tb12140.x. PMID: 2043916; PMCID: PMC1917868.
5: Costall B, Domeney AM, Naylor RJ, Tattersall FD. Emesis induced by cisplatin in the ferret as a model for the detection of anti-emetic drugs. Neuropharmacology. 1987 Sep;26(9):1321-6. doi: 10.1016/0028-3908(87)90094-3. PMID: 2890117.
6: McCallum RW. Review of the current status of prokinetic agents in gastroenterology. Am J Gastroenterol. 1985 Dec;80(12):1008-16. PMID: 4072997.
